内部人士在分析师的不同看法和最近的利中卖出了163万美元的Sionna Therapeutics股票. Insiders sold $163K in Sionna Therapeutics stock amid mixed analyst views and a recent earnings beat.

2025年12月17日至19日,锡永纳治疗学公司(SION)董事彼得·汤普森(Peter Thompson)和奥比梅德顾问有限责任公司(OrbiMed Advisors LLC)共出售3 650股,每股44.50美元左右,总共约163 450美元,将其股份减少0.02%至0.03%。 On December 17–19, 2025, Sionna Therapeutics (SION) director Peter Thompson and OrbiMed Advisors LLC sold a combined 3,650 shares at around $44.50 each, totaling roughly $163,450, reducing their stakes by 0.02% to 0.03%. 销售情况在证交会档案中披露,其内幕活动模式更为宽泛。 The sales were disclosed in SEC filings amid a broader pattern of insider activity. 据该公司报告,11月5日的季度损失为每股0.46美元,击打估计数为0.06美元。 The company reported a quarterly loss of $0.46 per share on November 5, beating estimates by $0.06. 尽管从 " 销售 " 到 " 强烈购买 " ,分析家的评级不一,但共识仍然是40.33美元的 " 中性购买 " 目标。 Despite mixed analyst ratings—ranging from “sell” to “strong buy”—the consensus remains “moderate buy” with a $40.33 target. 股票交易额接近42.37美元,市场上限为18.9亿美元,52周交易范围为7.26至45.00美元。 The stock traded near $42.37 with a market cap of $1.89 billion and a 52-week range of $7.26 to $45.00.